Recruiting

Testing a combination treatment for ovarian cancer that has come back

Plain-English translation of NCT07261683 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated June 2026 · How we translate trials

Read our Ovarian Cancer research guide →

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a combination of three medications works to treat ovarian cancer that has come back after initial treatment. The main medications being studied are weekly paclitaxel (or nab-paclitaxel), which is a chemotherapy drug; pembrolizumab, which is an immunotherapy drug that helps your immune system fight cancer; and mirabegron, a medication that may help support the immune response. The trial will measure whether this combination shrinks tumors and track what side effects patients experience.

Ovarian cancer that returns after initial treatment is difficult to treat, and doctors are looking for new approaches that are more effective. This trial is testing whether combining a traditional chemotherapy with an immunotherapy drug, along with an additional supportive medication, might help patients with recurrent ovarian cancer live longer and have better outcomes.

Do you qualify?

You likely qualify if…

you have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
your cancer has come back after you received initial platinum-based chemotherapy treatment
your cancer returned within 12 months of finishing your last treatment (or you have been treated with a non-platinum chemotherapy and it has been less than 12 months)
you have measurable disease that can be seen on imaging scans
you are in good enough health to tolerate treatment, with a life expectancy of at least 12 weeks
you have provided a tumor tissue sample from a prior surgery or new biopsy

You likely don't qualify if…

you have received prior immunotherapy treatments targeting PD-1, PD-L1, or similar immune checkpoint pathways
you have had a severe allergic reaction to paclitaxel, nab-paclitaxel, pembrolizumab, or mirabegron
you have had major surgery within the past 3 weeks
you have an active autoimmune disease or active infection requiring treatment
you are pregnant or breastfeeding

What participation looks like

You would receive the chemotherapy drug (paclitaxel or nab-paclitaxel) as an injection once a week, pembrolizumab as an infusion once every 3 weeks, and take mirabegron as a daily oral pill. You would visit the clinic every 2 months for checkups, imaging scans, and blood tests to monitor how well the treatment is working and how you are tolerating it. You would also keep a daily diary of your symptoms to help researchers understand how the medications are affecting you.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Testing a combination treatment for ovarian cancer that has come back

What is this trial?

Do you qualify?

What participation looks like

Trial locations